Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel and Carboplatin in mCRPC
NCT06470243Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2024
- Primary completion
- Jun 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SWOG Cancer Research Network. Started Nov 2024; status: recruiting.
02
Drugs
carboplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06470243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470243.